Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial

Area of Science:

• Hepatology
• Gastroenterology
• Pharmacology

Background:

• Severe alcoholic hepatitis (SAH) treatment efficacy, particularly corticosteroids, remains debated.
• Pentoxifylline (PTX), a tumor necrosis factor (TNF) inhibitor, has shown potential in reducing short-term mortality in SAH.
• This study investigates PTX's impact on mortality, renal, and hepatic functions in SAH patients.

Purpose of the Study:

• To evaluate the effect of Pentoxifylline (PTX) on short-term mortality in patients with severe alcoholic hepatitis (SAH).
• To assess the impact of PTX on renal and hepatic function in SAH patients.
• To determine changes in serum tumor necrosis factor (TNF) levels.

Main Methods:

• Prospective enrollment of 50 SAH patients with Maddrey's Discriminant Function (DF) ≥ 32.
• Randomized assignment to receive either PTX (400 mg thrice daily) or placebo for 4 weeks.
• Measurement of serum TNF levels, renal function (urea, creatinine), hepatic function (DF), and mortality.

Main Results:

• PTX group showed a trend towards lower mortality (20% vs. 40%) compared to placebo.
• Significant improvements in urea, creatinine, DF, and TNF were observed in the PTX group.
• Renal failure contributed to mortality in 20% of PTX patients versus 70% of controls, with a trend towards significance (p=0.11).

Conclusions:

• Pentoxifylline significantly improves renal and hepatic functions in SAH patients.
• PTX demonstrates a trend towards decreased short-term mortality in severe alcoholic hepatitis.
• Further research may clarify PTX's role in SAH management.